FINWIRES · TerminalLIVE
FINWIRES

Top Midday Decliners

By

Treasure Global (TGL) said Tuesday its Tadaa Technology unit has formed a partnership with Malaysia-based Kainan to provide AI-enabled technology services for a planned $367 million solar farm project.

Nevertheless, shares dropped 27%, with intraday trading volume rising to over 670,000 from a daily average of more than 323,000.

Celldex Therapeutics' (CLDX) two phase 3 trials of barzolvolimab in patients with chronic spontaneous urticaria met their primary and all key secondary endpoints at 12 weeks, the company said Tuesday.

Still, shares dropped 8.7% as intraday trading volume climbed to over 10.3 million from a daily average of more than 986,000.

Price: $2.15, Change: $-0.81, Percent Change: -27.36%

What else is happening in Wire?

Wire

Inghams Group Says Mitsubishi UFJ Financial's Stake in Firm Falls

Inghams Group (ASX:ING) said Mitsubishi UFJ Financial Group's voting power in the firm fell to 6.19% from 7.2% as of Sept. 16, according to a Tuesday Australian bourse filing.The Japanese bank holds nearly 23 million ordinary shares of the firm as of Sept. 16.Inghams Group's shares fell past 1% in recent trading on Tuesday.

ASX:ING
Wire

AnaptysBio Swings to Q2 Profit as Revenue Rises; Shares Gain After Hours

AnaptysBio (ANAB) reported Q2 net income late Monday of $5.11 per diluted share, swinging from the loss of $1.30 a year earlier.Revenue in the three months ended June 30 rose to $27.5 million from $22.3 million a year earlier.The company's shares rose 4.5% in after-hours trading.

$ANAB
Wire

Moderna Provides Details on Data Presentations at Upcoming Conferences

Moderna (MRNA) said Monday that phase 3 data for intismeran autogene in resected stage IIB-IV melanoma will be presented at a Presidential Symposium during the ESMO Congress 2026 on Oct. 24.The company said three abstracts on the investigational individualized neoantigen therapy were accepted for presentation, including data from a phase 1 pancreatic cancer study and a phase 3 lung cancer study.The company will also present in the Bernstein Insights Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum on Sept. 23, according to its website.Price: $173.39, Change: $+19.35, Percent Change: +12.56%

$MRNA